Following two successful Phase III studies last year, Acorda Therapeutics Inc. submitted its new drug application as expected for Fampridine-SR, hoping to gain approval of the first drug specifically aimed at improving walking ability in patients with multiple sclerosis. (BioWorld Today) Read More